INTRODUCTION
Forty percent of the world's population is at risk of malaria infection. Each year, 100 million people experience a malarial illness and over 1 million individuals (primarily African children) die (178) . In patients with severe and complicated disease, the mortality rate is between 20 and 50% (115) .
The parasite responsible for the vast majority of fatal malaria infections, Plasmodium falciparum, can kill patients in a matter of hours. Malaria has traditionally been treated with quinolines such as chloroquine, quinine, mefloquine, and primaquine and with antifolates such as Fansidar (sulfadoxinepyrimethamine). Unfortunately, most P. falciparum strains have now become resistant to chloroquine, and some, such as those in Southeast Asia, have also developed resistance to mefloquine and halofantrine; multidrug resistance is expected to develop in Africa soon (169, 170) .
The endoperoxides are a promising class of antimalarial drugs which may meet the dual challenges posed by drug-resistant parasites and the rapid progression of malarial illness. The firstgeneration endoperoxides include artemisinin (qinghaosu) and several semisynthetic derivatives (Fig. 1) . Artemisinin, the prototype, is a sesquiterpene lactone (Fig. 1A) . Its structure, which includes an endoperoxide bridge (C-O-O-C), is unique among antimalarial drugs. Dihydroartemisinin is the reduced lactol derivative of artemisinin (29) , and the semisynthetic derivatives (artemether, arteether, artesunate and artelinate) are ethers or esters of the lactol (Fig. 1B) . The first-generation artemisinin drugs are being used widely in Thailand, Myanmar, Vietnam, and China, where multidrug resistant parasites are common (49) .
The second-generation endoperoxides are synthetic compounds (Fig. 2) . Hundreds of these have been made; many resemble artemisinin, but others (trioxanes, tetraoxanes) are relatively dissimilar. Only one of these compounds, arteflene ( Fig. 2A) , has been taken beyond preclinical development.
In general, the endoperoxides have several advantages over existing antimalarial drugs. First, there is little or no crossresistance with other antimalarial drugs. Second, the endoperoxides clear the peripheral blood of parasites more rapidly than other available drugs do. Finally, resistance to the endoperoxides has not yet developed despite widespread clinical use (172) . However, there are also several disadvantages. The endoperoxides have short half-lives, and effective levels in plasma are sustained for only relatively brief periods. As a result, short-course treatment (less than 5 days) with the endoperoxides alone is generally associated with an unacceptably high rate (Ͼ10%) of recrudescent infections. Also, many of the drugs have poor oral bioavailability and the bioactivities of orally administered formulations are unpredictable.
Artemisinin and its derivatives are stage specific. Late-stage ring parasites and trophozoites are more susceptible to these drugs than are schizonts or small rings (2, 19, 41, 156) . They are also gametocytocidal (34, 82, 105, 126, 127, 130) . Liver stages of P. vivax and P. falciparum are not affected (28) , so these drugs are not radical curative or causal prophylactic agents.
Earlier work on artemisinin derivatives have been well summarized in reviews by Klayman (78, 79) , Lee and Hufford (84) , Trigg (160) , Hien and White (49) , and Woerdenbag et al. (176) . Structure-activity relationships are summarized in a recent review by Cumming et al. (30) . We will briefly discuss the chemistry and pharmacology of these compounds but will focus primarily on mechanisms of drug action and drug toxicity, clinical trials, and operational issues.
FIRST-GENERATION ENDOPEROXIDES
Artemisinin is a natural product and is found in the leafy portions of Artemisia annua (qinghao), a plant used by Chinese herbalists since 168 B.C. Initially a treatment for hemorrhoids, 1 liter of water steeped with a handful of qinghao leaves was later (340 A.D.) found to be effective in reducing fevers (78) . Crude ether extracts yielded compounds which were effective in mice infected with the murine malaria parasite, Plasmodium berghei. Chinese scientists then purified and determined the chemical structure of this sesquiterpene lactone in 1972, naming it qinghaosu (27, 78) (Fig. 1A) , although it is now generally called artemisinin. Cultivated A. annua plants produce the best yields of artemisinin (about 2% [dry weight]); yields from the wild range from 0.06 to 0.5%, depending on the variety of A. annua used (160) . The review by Woerdenbag et al. (176) provides a state-of-the-art discussion of the cultivation of A. annua and the purification of artemisinin.
The initial studies conducted by Chinese scientists demonstrated that artemisinin and various derivatives were effective at nanomolar concentrations in vitro against P. falciparum (28, 93) . This was confirmed by scientists at the Walter Reed Army Institute of Research (13) . In vitro tests showed little crossresistance with other antimalarial agents (10, 114) . (The reviews by Klayman [78] and Trigg [160] provide more detail about this phase of drug development.)
Artemisinin can be produced inexpensively. Formulations (250-mg tablets, 250-mg capsules, 100-mg suppositories) are manufactured in Vietnam and China and are registered in both countries (49) . The suppository formulation is unique among antimalarial agents and represents a promising route of administration because it can be given to malaria patients who are too ill to take medications by mouth (3). Patients, or their families, can administer artemisinin suppositories in the home, thus initiating treatment earlier than is possible with parenteral treatment, which necessitates travel to a health center.
Since artemisinin is poorly soluble in water or oil, watersoluble derivatives (artesunate and artelinate) and oil-soluble derivatives (artemether and arteether) have been synthesized (Fig. 1B) . Artemether, the methyl ether of dihydroartemisinin, has been widely used in China. Currently, it is manufactured under Good Manufacturing Procedures conditions in China and is being marketed commercially by the Chinese manufacturer in association with Rhone-Poulenc-Rorer-Doma, a French pharmaceutical company. Artemether injection (Paluther) is registered in Brazil, China, Burma, Thailand, and at least nine African countries (172) . Each 1-ml ampule contains 80 mg of artemether in peanut oil. Artemether capsules (40 mg) are also produced.
Arteether (Fig. 1B) is the ␤-ethyl ether of dihydroartemisinin (13) and appears to be similar in most respects to artemether. It is being developed cooperatively by the World Health Organization, the Walter Reed Army Institute of Research, and the Dutch company ACF Beheer, with help from the Government of the Netherlands (31) . Preclinical development and phase I clinical pharmacology studies have been completed (63) . Phase II trials in adult patients with nonsevere, multidrug-resistant falciparum malaria were completed early in 1995. Clinical trials of intramuscular formulations in patients with severe falciparum malaria were initiated in 1995 and will continue for approximately 2 years (32).
Artesunate (Fig. 1B) is a water-soluble hemisuccinate derivative; it is available as 50-mg tablets, as artesunic acid for injection (60 mg/ampule), and as a 200-mg suppository. The parenteral formulation is unstable in water, so it must be reconstituted with 5% sodium bicarbonate solution immediately prior to administration. Artesunate tablets and injection are registered in Brazil, China, Ghana, Burma, Thailand, and Vietnam (172) .
Artelinate (Fig. 1B) is a water-soluble derivative developed at the Walter Reed Army Institute of Research (93); it is as effective as artesunate and is more stable in solution. A transdermal formulation is effective in animals (80) .
Several hundred semisynthetic artemisinin derivatives, which are ethers or esters of dihydroartemisinin, have been prepared and tested by Chinese scientists (reviewed in references 30 and 102) and others (13, 67, 93-98, 137, 159) . Other semisynthetic artemisinin derivatives include the 9-alkyl derivatives (1), 10-deoxoartemisinins (62, 138) , and lactol ring-contracted derivatives (162 use; the system used in this paper [ Fig. 1 ] is the one used by Chemical Abstract Services.)
SECOND-GENERATION ENDOPEROXIDES
There are several reported methods for the total stereospecific synthesis of artemisinin (8, 145, 180 ; reviewed in references 167 and 188). These synthetic methods have allowed the synthesis of artemisinin derivatives which are not merely ethers or esters of the dihydroartemisinin lactol. Many of these compounds have increased stability and/or increased potency in vitro (9; for a review, see references 30 and 188).
The complex ring structure of artemisinin is not necessary for antimalarial activity; only the endoperoxide bridge is required. A group of simplified analogs, the trioxanes ( Fig. 2B and C), also has antimalarial activity both in vitro (56-58, 76, 130, 132-134, 136) and in vivo (125) (126) (127) 135) . These analogs all have the same endoperoxide-containing six-membered ring found in artemisinin but are much simpler to synthesize. Hundreds of these compounds have been synthesized and tested in vitro. Fenozan 50F (Fig. 2B ) is a particularly promising compound with activity against a variety of drug-resistant P. berghei strains (including strains resistant to artemisinin) (126, 127) . It is both gametocytocidal and sporontocidal in vivo (127) . WR 279137 (Fig. 2C ) and WR 279138 are effective against P. falciparum in Aotus monkeys (135) . All these compounds have potencies comparable to those of the artemisinin derivatives mentioned above.
Scientists at Hoffman-LaRoche have synthesized a somewhat different group of endoperoxides. The prototype for their compounds is yingzhaosu, another endoperoxide-containing compound discovered by Chinese scientists (92) . A series of yingzhaosu derivatives was synthesized (50) and tested both in vitro and in vivo (54) . One of these compounds, arteflene (Ro 42-1611), is quite effective in P. falciparum-infected patients (142, 150) . Unfortunately, it was not superior to the semisynthetic artemisinin derivatives and it is not being developed further (140) .
Tetroxanes (161) and a naturally occurring plant-derived diterpene peroxide (66) are other organic peroxides with antimalarial activity.
MECHANISM OF ACTION
Artemisinin and its derivatives are toxic to malaria parasites at nanomolar concentrations, whereas micromolar concentrations are required for toxicity to mammalian cells (83, 175 (64, 111) to more than 100-fold-higher concentrations than do uninfected erythrocytes. The uptake is rapid, reversible, and saturable and appears to be at least partially dependent on metabolic energy (43, 64) .
Artemisinin derivatives are hydrophobic and partition into biological membranes. Radiolabeled dihydroartemisinin for example, associates with isolated erythrocyte membranes (although not with intact erythrocytes) (5). Ultrastructural autoradiographic studies of [ 3 H]dihydroartemisinin-treated parasites shows that the drug is present in the parasite limiting membranes (38) , digestive vacuole membranes (38, 104) , and mitochondria (104) . Thus, the artemisinins localize in specific parasite membranes.
Once inside the parasite, how do the artemisinin derivatives act? Considerable evidence has accrued that the killing of parasites is mediated by free radicals. One piece of evidence is the observation that artemisinin derivatives lacking the endoperoxide bridge, a known source of oxygen free radicals, are devoid of antimalarial activity (13, 78) . Further evidence includes observations that the in vitro antimalarial activities of artemisinin and artesunate are enhanced by high oxygen tension and by the addition of other free-radical-generating compounds, such as doxorubicin, miconazole (81), castecin, and artemitin (36) . Similarly, antioxidants (free-radical scavengers) such as ␣-tocopherol, catalase, dithiothreitol (81) , ascorbate, and reduced glutathione (112) block antimalarial activity. Conversely, ␣-tocopherol deficiency enhances the antimalarial action of artemisinin against P. yoelii in mice (85) and inhibitors of endogenous antioxidants promote artemisinin action (68) . In aggregate, the observed potentiation of the artemisinins by other oxidant agents and the inhibition of artemisinin action by antioxidants provides strong indirect evidence for the importance of free radicals.
Most free-radical-generating drugs cause ''oxidant damage'' by producing oxygen free radicals, such as superoxide, which then cause indiscriminate damage to the cell (44a). Artemisinin derivatives were at first thought to act in this manner (81, 112) . Artesunate was shown to induce lipid peroxidation (112) in both infected and uninfected erythrocytes, as well as membrane protein thiol oxidation in isolated erythrocyte membranes (111) . These artemisinin-induced membrane effects could underlie other observed effects of artemisinin derivatives, such as hemolysis (44, 146) , decreased erythrocyte deformability (146) , and premature lysis of infected erythrocytes (42) . However, lipid peroxidation, membrane thiol oxidation, and most of the other effects could be observed only at very high drug concentrations (Ͼ100 M), suggesting that these nonspecific oxidant reactions may not be mediating artemisinin killing of parasites.
Artemisinin derivatives have now been shown to affect parasites very differently from other oxidant drugs. Instead of reacting with oxygen and producing large quantities of oxygencontaining free radicals such as superoxide and OH˙, artemisinin itself becomes a free radical in a reaction catalyzed by iron (108) . A large body of data has now accumulated to support this mechanism.
In vitro, heme and iron catalyze the conversion of artemisinin and its derivatives into free radicals in a manner similar to the way that they catalyze the decomposition of hydrogen peroxide into free radicals (44a). By using cycle voltammetry, it was shown that heme causes a 0.6-V shift in the reduction potential of artemisinin, indicating that heme accelerates the decomposition of artemisinin by several orders of magnitude (189) . The iron-catalyzed generation of a free radical from artemisinin was confirmed by electron paramagnetic resonance spectroscopy (113) and by studies of isolated erythrocyte membranes (168) . The mechanism of iron-mediated decomposition of artemisinin derivatives in vitro has been determined by the structural elucidation of the decomposition products and by mechanistic studies on their rates of formation. The reductive cleavage of the endoperoxide bridge involves the transfer of an electron from ferrous iron (Fe [II] ) and the formation of Fe[IV]AO (129) . The endoperoxide bridge is cleaved first (131); this is followed by intramolecular electronic rearrangements which produce carbon-centered radicals (55, 131, 134, 136) . The carbon-centered free radical may be important in the mechanism of action, since derivatives which cannot form such radicals have no biological activity (130) . A highly electrophilic epoxide, a potent alkylating agent, is also formed after the cleavage (129), as is a 1,5-diketone, another potent alkylating agent (128a) . The importance of the generation of alkylating VOL. 60, 1996 ANTIMALARIAL ENDOPEROXIDES 303 agents by the iron-mediated decomposition of endoperoxides will become apparent later in this section.
Computational and molecular modeling studies have also supported the importance of the artemisinin-heme interaction. Docking studies with the computer program SYBYL have shown that artemisinin and heme dock in a configuration which allows the heme iron to cleave the endoperoxide bridge (146a). In addition, comparative molecular field analysis of a large series of artemisinin derivatives has elicited a pharmacophore (receptor) structure which is consistent with heme (9). Finally, for a series of trioxanes, it was shown that conformation but not chirality is associated with biological activity, which is again consistant with heme being the receptor, since heme is achiral (56) .
Not only does heme catalyze the breakdown of artemisinin, but also it forms a covalent complex with it. When hemin and artemisinin are mixed in solution, they form covalent adducts with molecular weights of 856 and 871 (53) . The adducts appear to contain one heme molecule plus one artemisinin molecule and to have retained the heme iron (110) but to have lost small fragments of either the artemisinin or porphyrin structures. Repeated attempts to elucidate the structures of these adducts were unsuccessful, but on the basis of a large number of studies of the interactions of drugs with heme in cytochrome P-450, it is likely that artemisinin has alkylated the porphyrin ring at either the pyrrole nitrogen or the meso carbon (122a).
Thus, a number of observations from several laboratories are consistent in showing an interaction between heme or iron and artemisinin derivatives to generate free radicals and other reactive intermediates. However, many of these data were obtained from experiments with defined cell-free solutions. Do these reactions also occur within malaria parasites?
Artemisinin-heme adducts are formed when infected erythrocytes are incubated with radiolabeled drug in vitro, since the drug-derived radioactivity comigrates with synthetic adducts on both thin-layer chromatography and high-performance liquid chromatography (HPLC), (53, 111) . The adduct forms when infected erythrocytes are incubated in the presence of 60 nM artemisinin (53), a concentration which is similar to its in vitro 50% inhibitory concentration (IC 50 ) (10 to 20 nM in reference 112), suggesting that the drug-heme adducts form in the presence of pharmacologically relevant concentrations of drug.
Is the formation of artemisinin-heme adducts responsible for killing the parasite? A reaction between artemisinin and heme could lead to parasite death via several different mechanisms. The artemisinin-heme adduct itself might be toxic to the parasite. However, in vitro data suggest that the artemisinin-heme adduct has little antimalarial activity (111) . Another possibility is that free iron is released during the reaction with artemisinin, since other alkyl peroxides have been shown to degrade heme (122a). The released iron might then be toxic to the parasite. However, free iron does not increase to detectable levels in artemisinin-treated parasites (110) . Finally, the artemisinin-heme adduct might either inhibit hemozoin synthesis or cause its degradation. In vitro data suggest otherwise because there was no effect of artemisinin treatment on the hemozoin content of parasites in culture, even at concentrations which inhibit hypoxanthine incorporation (6) . Therefore, adduct formation between artemisinin and heme does not seem to explain the antimalarial activity of the drug. In other words, while the artemisinin-heme adduct forms in drugtreated parasites, its formation may be unrelated to the mechanism of action of the drug.
Artemisinin is also capable of alkylating proteins and this reaction appears to be more important. Both artemisinin and dihydroartemisinin form covalent complexes with albumin in vitro, and the complex is formed more quickly in the presence of heme. The covalent nature of the complexes has been confirmed by electrospray mass spectrometry; there appear to be two molecules of drug attached to each molecule of albumin (183) .
When artemisinin reacts with hemoproteins, it alkylates the protein portion, not the heme. For example, there is almost no reaction between globin and dihydroartemisinin in solution, but there is a marked reaction between hemoglobin and dihydroartemisinin (184); the difference is clearly due to the presence of heme. However, when dihydroartemisinin reacts with hemoglobin, most of the drug molecules bind to the protein (globin) portion of hemoglobin, not to heme (183) . Thus, the electrophilic intermediate formed from artemisinin in the presence of heme alkylates the protein portion preferentially to heme.
Artemisinin, unlike other alkylating agents, does not react with DNA (184) .
There is a marked and reproducible reaction between artemisinin derivatives and several proteins when malaria-infected erythrocytes are exposed to artemisinin derivatives. Malariaspecific proteins with molecular masses of 25, 32, 42, 50, 65, and Ͼ200 kDa become radioactive when the P. falciparuminfected erythrocytes are incubated with radioactive artemisinin derivatives (7) . There is no reaction between artemisinin derivatives and any protein in intact erythrocytes. The reaction between the artemisinin derivatives and the malarial proteins appears to be specific, since the target proteins are not particularly abundant on Coomassie blue-stained gels. Labeled proteins can be observed in parasites that were treated with 33 nM dihydroartemisinin, a concentration that is similar to its IC 50 (112) and is thus pharmacologically significant. Radiolabeled arteether, dihydroartemisinin, and arteflene react with the same proteins. In contrast, radiolabeled deoxyarteether, an inactive derivative, does not react with any malarial proteins even when present at a 20-fold-higher specific activity than arteether (7) . Importantly, the labeled proteins seem to be concentrated in a crude parasite membrane fraction (7), which is consistent with the affinity of the drug for membranes discussed above. During short incubations with dihydroartemisinin (1 h), only the 25-and Ͼ200-kDa proteins react with drug (123) . Such a rapid effect is probably physiologically relevant, since it has been shown that artemisinins kill parasites within 4 h (2, 104). Thus, one or both of these malarial membrane proteins may be the critical artemisinin receptor.
It is unclear whether intraparasitic pool of iron or heme is responsible for activating the artemisinin derivatives in vivo. One possibility is the iron and heme present in the parasite's food vacuole, where 25% of the host erythrocyte's hemoglobin is digested (141) and hemoglobin heme is liberated and incorporated into hemozoin granules (141) . When P. falciparum is incubated in the presence of a radiolabeled artemisinin derivative, as much as half of the parasite-associated radioactivity can be found in isolated hemozoin (53, 111) , presumably in the form of drug-heme adducts. The association of drug-derived radioactivity with hemozoin has also been demonstrated by electron-microscopic autoradiography (104) . Furthermore, mice infected with P. berghei RC, which does not synthesize visable hemozoin, require 50-fold more artemisinin for a cure than those infected with the N strain, which does make hemozoin (124) . However, artemisinin reacts poorly, if at all, with hemozoin in vitro (53) , probably because only the iron atoms at the surfaces of the granules are available to serve as catalysts. Instead, in vivo, the artemisinins probably react with heme molecules in transition between hemoglobin and hemozoin or with iron released from the heme by the acidic environment of the food vacuole (40) . The interaction with transitional heme molecules would be consistent with observations that chloroquine is antagonistic with artemisinin in vitro (152) , since chloroquine binds extremely tightly to heme (29a) and might block its interaction with artemisinin. The interaction with free iron would be consistent with the observation that iron chelators antagonize the antiparasitic effect of the artemisinins in vitro (68, 113) . Alternatively, the activation step could occur outside the food vacuole, in other parts of the cell such as the cytoplasm or mitochondrion, and be catalyzed by other malarial hemoproteins such as cytochromes (39a) or catalase (38a) .
In addition to the food vacuole (104), other organelles appear to be affected at early times after artemisinin treatment. Electron micrographs of parasites exposed to artemisinin or artemether reveal early damage to parasite mitochondria, rough endoplasmic reticulum, and the nuclear envelope (38, 59, 74, 104) . There are three possible explanations for this. First, artemisinin may be activated into its electrophilic (alkylating) metabolite in the food vacuole, and this metabolite may then diffuse out and attack other organelles. Second, artemisinininduced damage to the food vacuolar membrane (104) could cause other organelles to be damaged as a result of leakage of food vacuole contents. Third, artemisinin might be activated outside the food vacuole by various hemoproteins, as mentioned above. However, although ultrastructural data suggest that the mitochondrion is a target (59), artemisinin has no effect on mitochondrial electron transport (53a), calling the significance of the ultrastructural findings into question.
In summary, the antimalarial endoperoxides appear to have a two-step mode of action (Fig. 3) . In the first step, artemisinin compounds are activated by heme or molecular iron to produce free radicals and electrophilic (alkylating) intermediates. In the second step, these reactive species react with and damage specific malaria membrane-associated proteins (109) . Thus, artemisinin derivatives are free-radical generators but are different from ''oxidant'' free-radical-generating drugs in two ways: (i) the resulting free radicals are carbon centered, and (ii) there are specific target proteins (108) . The identities of the artemisinin target proteins await elucidation.
METABOLISM AND PHARMACOKINETICS
The metabolism of artemisinin and its derivatives has been studied both in vitro and in vivo (reviewed in references 24 and 84). Artemisinin is converted primarily into inactive metabolites such as deoxyartemisinin and dihydrodeoxyartemisinin. Both arteether and artemether, in contrast, are converted into a number of metabolites with retained antimalarial activity (24) . These include dihydroartemisinin and a variety of other (Fig. 4) . Inactive deoxydihydroartemisinin is also formed. Both artesunate and artelinate are rapidly converted into dihydroartemisinin, which probably accounts for all their antimalarial activity (84) . In healthy, normal volunteers, orally administered artemisinin is metabolized primarily in the liver. Because this first-pass effect is significant, the bioavailability of the oral preparation relative to an intramuscular suspension in oil is only 32% (158) .
Pharmacokinetic studies have been hampered by the difficulties encountered in developing a reproducible assay for the primary drugs and their metabolites. A variety of methods, such as the use of radiolabeled drug and of a radioimmunoassay, have been reported (151) , but these methods cannot distinguish between the parent compound and its metabolites. Largely for this reason, there are no detailed studies on the relationship between antimalarial activity and drug concentrations in plasma, and so it has not been possible to rationalize drug regimens by a traditional pharmacokinetic approach. An in vitro assay which quantitates the overall antimalarial activity (parent drug plus metabolites) in plasma has been used for pharmacodynamic studies (91, 156) , and HPLC methods, involving electrochemical reduction (106, 121) and derivatization with UV detection (116, 157) , have been developed.
There have been a few studies of the pharmacokinetics of artemisinin derivatives in human volunteers, in which HPLC was used to measure drug levels in plasma. Unfortunately, only the parent compounds were monitored, so we still know little about the appearance and disappearance of biologically active metabolites (24) . After oral administration, concentrations of artemisinin in the blood were found to peak at 0.5 h (158) and 1.8 h (33) and to be eliminated with a half-life (t 1/2 ) of 1.9 h (158) and 2.6 h (33). Oral artemether was found to have similar properties, peaking at 1.8 h (121) and 3 h (120) and disappearing with a t 1/2 of 1.1 h (121) and 3.1 h (120). Thus, both artemisinin and artemether are eliminated from the plasma with t 1/2 of 1 to 3 h when administered orally. Intravenous artesunate is eliminated even more quickly. Artesunate is converted almost immediately into dihydroartemisinin, which is then eliminated from the plasma with a t 1/2 of 45 min (151). Intramuscular administration is associated to the slowest elimination because the drugs are dissolved in oil (peanut or sesame oil) and, when injected, probably form a depot from which drug is released slowly. Artemether concentrations peak 5 to 6 hours after intramuscular administration and disappear with a t 1/2 of 8 to 11 h (151). Intramuscularly administered arteether peaks at 1.5 h and is eliminated with a t 1/2 of 23 h (63).
There are no publications to date describing the pharmacokinetics of artemisinin derivatives in malaria patients or in patients with thalassemia. The drugs are likely to behave differently in the different patients, given the rapid uptake of drug by infected and thalassemic erythrocytes (64) . Also, the artemisinins are highly (70 to 80%) protein bound (90, 165) , mainly to ␣-1-acid glycoprotein, an acute-phase protein whose level is markedly elevated in acute malarial illness (165) .
In summary, there is a striking paucity of data on the pharmacokinetics of the artemisinin derivatives. Hopefully, this situation will be remedied in the near future.
INNATE RESISTANCE TO ANTIMALARIAL EFFECTS OF THE ARTEMISININS
Thalassemia appears to confer resistance to malaria infection in vitro and in vivo (reviewed in references 166, 186, and 187), but, paradoxically, parasites infecting ␣-thalassemic erythrocytes, instead of being more susceptible to the artemisinins than parasites in genetically normal erythrocytes, are more resistant to them (64, 185) . The mechanism of increased drug resistance in two ␣-thalassemia variants, Hb H and HbH/Hb Constant Spring, has been explored. Uninfected thalassemic cells accumulate [ 14 C]artemisinin to a much greater extent than do uninfected normal cells and thus deplete the pool of drug available for uptake by infected thalassemic cells (64) . These findings may be important in parts of the world (such as Southeast Asia) where thalassemias are common.
TOXICITY
Although there is no clinical evidence for neurotoxicity in humans, high doses of artemisinin derivatives are neurotoxic in vitro and in experimental animals. Brewer et al. (11, 12) have shown that dogs administered six daily doses of arteether at 20 mg/kg/day or 28 daily doses of 15 mg/kg/day develop neurological symptoms, neuropathological findings, and electrocardiographic abnormalities. Similar neuropathological changes were obtained in rats by administering either arteether or artemether at doses as low as 25 mg/kg/day for 14 days. In both dogs and rats, lesions were most pronounced in the brain stem. Histopathologically, neuronal cells had undergone degeneration, showing a loss of Nissl substance and the presence of nuclear pyknosis. These results have recently been confirmed in studies of rats by Kamchonwongpaisan et al. (65) , although no neuropathology could be detected at total doses less than 250 mg/kg.
Artemisinin derivatives are also toxic to neuronal cells in vitro. Wesche et al. (171) demonstrated that a series of artemisinin derivatives inhibited protein synthesis by two neuroblastoma cell lines and by primary fetal rat neuronal cells. Artesunate and dihydroartemisinin were the most toxic derivatives, with IC 50 s of Ͻ1 M. Fishwick et al. (39) also observed toxicity to neuroblastoma cells in vitro and found toxicity to glioma cells in vitro as well. Surprisingly, these authors found artemether to be more toxic than dihydroartemisinin in inhibiting neuroblastoma cell proliferation. Several artemisinin derivatives significantly inhibited neurite formation in neuroblastoma cells at 100 nM.
The toxicity of artemisinin derivatives to neuronal cells may also be iron dependent, since heme potentiates the toxicity of artemisinin derivatives to neuroblastoma cells in vitro (149) . An iron chelator also inhibits the acute toxicity of artemisinin to mice (113) , although no effect of this chelator could be demonstrated on arteether-induced neuropathology in rats (65) . The toxic effect of artemisinin derivatives on neurons appears to involve protein alkylation (65) . Thus, the mechanism of neurotoxicity is similar in many respects to the mechanism of antimalarial action.
In summary, high doses of the artemisinins appear to have specific neurotoxic effects both in vitro and in vivo. However, since the drug has been used safely in millions of people, this neurotoxic effect is unlikely to be clinically relevant.
OTHER USES OF ARTEMISININ DERIVATIVES
Artemisinin derivatives are active against Schistosoma mansoni and Schistosoma japonicum in vitro and in experimental animals (144, 179) . This is of mechanistic interest, since schistosomes, like malaria parasites, degrade hemoglobin and produce hemozoin (52) . Activity has also been demonstrated against Leishmania major (181) , Toxoplasma gondii (20, 51, 75, 182) , and Pneumocystis carinii (107) in vitro and against P. carinii in vivo (23) .
Artemisinin derivatives have immunosuppressive activity (22, 154) and also, potentially, anticancer activity (83, 175) . The activity of artemisinin against cancer cells was potentiated if the cancer cells were first loaded with iron by exposure to transferrin (83) .
The concentrations or doses of artemisinin derivatives which are necessary for these alternate activities in vitro and in vivo are substantially higher than those required for antimalarial activity. Therefore, antimalarial endoperoxides are not likely to be useful for other therapeutic purposes. However, directed-synthesis programs might lead to endoperoxides with useful anti-infective or anticancer activities (175) .
CLINICAL STUDIES
Artemisinin and its derivatives have become important components of the malaria control efforts in parts of the world (primarily Southeast Asia) where multidrug-resistant P. falciparum infections are common. These drugs were propelled into their current positions by necessity; the rapid evolution of multidrug-resistant parasites compelled public health officials to sanction their use, even though they had not emerged from conventional drug development programs. As a result of the unorthodox process, a number of new questions have emerged regarding the deployment of these drugs, and malaria control programs find themselves in the unusual position of having to generate both data and policies regarding these drugs more or less simultaneously.
Indications for Use
In settings where the malaria parasites remain sensitive to the existing antimalarial drugs (both parenteral and oral formulations), do the artemisinins confer any advantage? This is an important consideration, because widespread use of a drug enhances the likelihood that drug resistance will develop. Accordingly, the use of any antimalarial drug should be restricted to situations in which it confers distinct advantages (169) . The artemisinins have not yet been demonstrated to be superior in areas such as sub-Saharan Africa, where chloroquine, sulfadoxine-pyrimethamine, and mefloquine are effective for the treatment of uncomplicated malaria and quinine remains efficacious for the treatment of severe and complicated malaria. Premature and unregulated use of the artemisinins, especially oral dosage forms, could accelerate the development of drug resistance, thus compromising the efficacy of these drugs when multidrug resistance develops in Africa (177) .
Safety
Another important question centers on drug toxicity. In many settings, antimalarial treatment is prescribed presumptively; i.e., health care workers decide that antimalarial treatment is warranted on the basis of the clinical syndrome. Diagnostic blood tests are often not possible. As a result, many patients who are not infected with malaria parasites receive antimalarial drugs; in one recent study, only 30% of Malawian adults for whom presumptive antimalaria therapy was prescribed were actually parasitemic (61) . Furthermore, individuals living in areas where malaria is endemic might become reinfected with malaria several times during a transmission season and might receive several doses of antimalarial drugs each year. In addition, individuals frequently elect to treat themselves or a family member for malaria, and because of the widespread availability of over-the-counter antimalarial chemotherapy in shops and markets, these medicines can be easily obtained and used any time and as often as deemed necessary.
Self-treatment, presumptive treatment, and repeated treatment of uncomplicated infections are most frequently performed with oral-dosage forms, because these are most convenient for outpatients. The question of drug toxicity, particularly with chronic or repeated use, becomes very important once a drug is released and is widely available.
The safety of this class of drugs has been in question because the early preclinical and clinical studies did not meet the stringent requirements of Western and international drug-regulating agencies. Over two million patients are estimated to have been treated with artemisinin or its derivatives, and no adverse effects have been noted (172) : this admittedly anecdotal record is corroborated by the clinical trials conducted thus far in which toxicity has been limited to sporadic reports of mild, transient cardiac dysrhythmias (71, 73, 117, 174) . Transient dose-related reductions in reticulocyte counts were noted in some early preclinical toxicology studies (26) but have not been observed in human clinical trials. Fetal resorption was observed in some animal toxicology studies (26) , so these drugs should be used during pregnancy only as a last resort (177) .
There are few data on the cumulative toxicity of the artemisininsin in humans, but given the neurotoxicity reported in animal models (11, 12) and in vitro (171), it is important to obtain such data. However, because oral-dosage forms are already in wide use (177) , collecting this information will be challenging. Thailand has established a system for postmarketing surveillance of the safety and efficacy of artesunate and artemether (128, 177) , and this may serve as a model for other countries in which these drugs are sanctioned for widespread use.
Efficacy
How should efficacy be defined for these (and other) antimalarial drugs? Efficacy depends on the indication for which a drug is being used, and the definition may be different for drugs used as first-line treatment for uncomplicated infections and for drugs recommended for the treatment of severe disease. ''Parasitologic cure'' is the end point measure of efficacy for patients with uncomplicated infections; ''survival'' is the primary end point for patients with severe disease (172) . A oral drug or drug combination which can produce a 28-day cure rate in excess of 90% might be very practical as first-line treatment for uncomplicated malaria, but it might not be the optimal life-saving regimen for patients with life-threatening infections. Similarly, while treatment with a particular parenteral preparation might confer a significant survival advantage over other treatments in patients with cerebral malaria, it might well be associated with recrudescence rates in excess of 10%. Survivors can easily receive another treatment to effect parasitologic cure. It may be both unnecessary and unrealistic to expect a single drug, or even one drug regimen, to serve the dual purposes of achieving 28-day parasitologic cures and decreasing the mortality associated with severe and complicated malaria. Interpretations of the antimalarial efficacy of the artemisinins should be considered in the context of these two different expectations, and we have grouped the available data accordingly (Tables 1 to 3 ).
Artemisinins as First-Line Treatment for
Uncomplicated Malaria The ideal first-line treatment for uncomplicated malaria would be an affordable, nontoxic oral formulation capable of eradicating erythrocytic and preerythrocytic parasites with a single dose. In general, a patient is considered cured if he or she becomes aparasitemic within 7 days of starting treatment VOL. 60, 1996 ANTIMALARIAL ENDOPEROXIDES 307
on February 21, 2013 by PENN STATE UNIV http://mmbr.asm.org/ and remains aparasitemic for 28 days (169). However, up to 50% of patients treated with artemisinin derivatives alone may recrudesce (become parasitemic again after having cleared the initial parasitemia) within 28 days (Table 1) . The frequency of recrudescences may be overestimated because, in practice, it is difficult to distinguish between reinfection and recrudescence unless patients are kept in a transmission-free area. To achieve a 28-day cure with artemisinin drugs alone, treatment courses of 5 to 7 days are generally required (Table 1) . Since the clinical symptoms of most patients improve rapidly following treatment with these drugs, however, the patients are less likely to continue treatment courses lasting longer than 3 to 4 days (103). This apparent necessity for sustained courses of monotherapy with the artemisinins stems from the short half-lives of the parent compounds and the active metabolites in plasma (see above).
One approach to the problem of recrudescence following short courses of artemisinin monotherapy is to use combination chemotherapy involving artemisinin or a derivative plus another antimalarial agent. The second agent must be chosen carefully; there is in vitro evidence of drug-drug antagonism with chloroquine (152) and in vivo evidence of antagonism with antifolates (21) . In contrast, in vitro synergy between arteether and both mefloquine and quinine (35) and in vivo synergy between artemisinin and both mefloquine and tetracycline (21) have been demonstrated. Combination regimens have the advantage of a shorter duration of treatment, thus increasing the likelihood that patients will complete the entire course and be cured. Various regimens have been evaluated (Table 2) , and several are effective. The selection of a particular regimen is likely to depend on local parasite sensitivities, the target population (e.g., tetracyclines are contraindicated in 
Artemisinins as Treatment for Severe and Complicated Malaria
The goal in treating patients with severe and complicated malaria is survival, not parasitological cure (172) . Clinical trials with mortality-based end points require large numbers of patients; several large studies comparing intramuscular artemether with parenteral quinine are in progress, but no published data are available yet. The studies which have been published either have described the efficacy of artemisinin or a derivative alone or have compared various of the artemisinins with standard treatments for severe malaria (Table 3) . These studies have been large enough to demonstrate shorter parasite clearance times in patients receiving artemisinin or artemisinin derivatives (Table 3) , but the clinical significance of that advantage, in terms of mortality, has yet to be determined. Meta-analyses of already published and soon-to-be-published studies may be necessary to derive the data required to inform 
OPERATIONAL ISSUES
The development of the artemisinin class of antimalarial drugs has been stymied by the difficulties encountered in developing analytical methods to measure the concentration of drug in plasma (see above). Because of the pressing need for new drugs to treat patients with multidrug-resistant parasites, treatment regimens involving these compounds, alone or in combination with existing drugs, have been developed empirically and evaluated in a variety of different clinical settings. As a result, it is difficult, on the basis of the available data, to determine which of the derivatives is superior for any given indication, which routes of administration are best, which drug combinations are advisable, or even which dosage regimens are optimal. However, on the basis of the pharmacokinetic and pharmacodynamic data available, it is clear that these drugs are not well suited for chemoprophylaxis and should not be recommended for this purpose (172, 177) .
The rapidly evolving need for effective drugs in settings in which multidrug resistance is common has also outstripped the traditional regulatory processes for new-drug development. The artemisinin drugs are being produced and used widely throughout Southeast Asia, and their use is increasingly promoted in Africa (172, 177) , but they cannot be manufactured or distributed by European or North American pharmaceutical companies until the regulatory requirements of the respective countries have been met. While the unregulated use of the artemisinins increases the likelihood that drug resistance will develop and decreases the likelihood that adverse effects will be reported systematically, it is difficult to imagine restricting their use in the face of a pressing need for effective drugs. A ''fast-track'' approach to the regulatory status of these drugs, akin to that developed for promising retroviral therapies (77), may be one realistic approach to this real-world dilemma.
At present time, the World Health Organization recommends that use of the artemisinin drugs be determined by the local drug sensitivities (177) . In areas where multidrug resistance is common, artemisinin or artesunate can be administered orally or as rectal suppositories to treat patients with uncomplicated malaria. When other orally administered drugs (e.g., mefloquine) contribute to efficacy, combination treatments will decrease the duration of treatment and should be used. Parenteral formulations of the artemisinins (intramuscular artemether, intravenous or intramuscular artesunate) should be used only in areas where quinine resistance is demonstrable. The use of the artemisinin drugs in areas where multidrugresistant malaria is rare or absent is not recommended. If data from the large clinical trials recently completed suggest an advantage, this recommendation may be modified. At this time, however, there are effective oral drugs which are less expensive than the artemisinins, and quinine remains an effective treatment for severe disease. The availability of suppository formulations of the artemisinin allows home-based treatment of patients who are too ill to take antimalarial drugs by mouth. This might confer a significant advantage, because treatment could be started earlier, thus avoiding the delays incurred during travel to a health clinic (3). However, conclusive evidence for the effectiveness of these formulations in this situation has not been obtained.
CONCLUSIONS
The artemisinin group of drugs is the most important new class of antimalarial agents introduced since World War II. Despite having followed an unorthodox path of drug development, these drugs are already being used widely, particularly in parts of the world where multidrug-resistant P. falciparum is common. Expectations of toxicity based on findings in animal models have not been borne out in the clinical experience with these drugs. However, there is little experience with repetitive or chronic use, and as these drugs begin to penetrate areas where malaria is endemic it would be advisable to establish systems to detect serious adverse effects.
The first-generation endoperoxides have their limitations, though, such as high recrudescence rates, poor oral bioavailability, and short half-lives. Second-generation endoperoxides may improve these features and, perhaps, be even less expensive. The development of second-generation endoperoxides should be aided by our knowledge of their mechanism of action. The development of these new derivatives, however, is likely to be hindered more by economic and political issues than by scientific ones.
How should the new derivatives be evaluated? Clinical measures of treatment efficacy should be determined in the context of the disease being treated; parasitological cure is the goal in patients with uncomplicated malaria, and survival is the important end point in patients with severe and complicated disease. Combinations of an artemisinin drug with another antimalarial agent are potentially more effective in patients with uncomplicated malaria because they are curative and can be administered over shorter periods. The duration of treatment is a less important consideration for patients with severe and complicated disease; in these patients, a rapidly effective, life-saving drug is required and radical cures can be accomplished at a relatively leisurely pace in the survivors.
In summary, the artemisinin derivatives are a highly promising new group of antimalarial agents. Second-generation derivatives may become widely used in the future. First-generation compounds are currently indicated in parts of the world where resistance to other antimalarial drugs is common. Premature and unregulated use of the artemisinins, especially oral formulations, should be avoided, because it might hasten the development of resistance.
